Browsing by Author "Liu, Shuai"
Now showing items 1-4 of 4
-
Development of Dimethylisoxazole-Attached Imidazo[1,2‑a]pyridines as Potent and Selective CBP/P300 Inhibitors
Muthengi, Alex; Wimalasena, Virangika K.; Yosief, Hailemichael O.; Bikowitz, Melissa J.; Sigua, Logan H.; Wang, Tingjian; Li, Deyao; Zhang, Wei; Qi, Jun; Schönbrunn, Ernst; Amaro, Rommie E.; Erickson, Jon; Liu, Shuai; Dhawan, Gagan; Gaieb, Zied (2021)The use of epigenetic bromodomain inhibitors as anticancer therapeutics has transitioned from targeting bromodo main extraterminal domain (BET) proteins into targeting non-BET bromodomains. The two most relevant non-BET ... -
One-pot and catalyst-free synthesis of pyrroloquinolinediones and quinolinedicarboxylates†
Zhang, Xiaofenga; Dhawan, Gagan; Muthengi, Alex; Liu, Shuai; Wang, Wei; Legrisa, Marc; Zhang, Wei (2017)A method for the catalyst-free synthesis of pyrroloquinolinediones and quinolinedicarboxylates is develo ped through a one-pot synthesis involving denitrogenation of azide, benzisoxazole formation, aza-Diels– Alder ... -
Stereoselective synthesis of fused tetrahydroquinazolines through one-pot double [3 + 2] dipolar cycloadditions followed by [5 + 1] annulation
Zhangg, Xiaofeng; Pham, Kenny; Liu, Shuai; Legris, Marc; Muthengi, Alex; Jasinski, Jerry P.; Zhang, Wei (2016-10)The one-pot [3 + 2] cycloaddition of an azomethine ylide with a maleimide followed by another [3 + 2] cycloaddition of an azide with the second maleimide gives a 1,5-diamino intermediate which is used for a sequential ... -
Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors
Liu, Shuai; Yosief, Hailemichael O.†; Dai, Lingling; Huang, He; Dhawan, Gagan; Zhang, Xiaofeng; Muthengi, Alex; Roberts, Justin; Buckley, Dennis L.; Perry, Jennifer A.; Wu, Lei; Bradner, James E.; Qi, Jun; Zhang, Wei (2018)The simultaneous inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are ...